Pharmasaga Returns to the US BIO Convention 2026! 🌍 Deepening Global Partnerships & Advancing Clinical Development
Kicking off on June 22nd for four action-packed days, the Pharmasaga team is thrilled to participate once again in the premier global biotech partnering event. We are engaging with leading pharmaceutical companies, investors, and industry partners from around the world to drive our global expansion strategy. 🤝
The BIO Convention is the ultimate hub for international collaboration. For Pharmasaga, it's a pivotal opportunity to share the latest clinical milestones of our core asset, PS-001, and actively explore out-licensing, co-development, and strategic investments.
🔬 Highlighting PS-001:
As a First-in-Class PDIA4 inhibitor, PS-001 takes a breakthrough approach to treating both Type 2 and Type 1 diabetes by attenuating islet cell failure and driving endogenous beta-cell replenishment.
🚀 Day 1 Milestones:
We've already hit the ground running with highly productive one-on-one partnering meetings:
Conducted follow-up meetings with 2 global pharmas to discuss potential out-licensing and co-development opportunities.
Exchanged strategic insights with 1 international investment firm regarding future funding collaborations.
Connected with 2 global CROs to map out the execution plans for our upcoming global Phase II clinical trials.
As we actively prepare for our global Phase II IND and trial initiation, the partnerships forged and strengthened at BIO 2026 will be instrumental in accelerating our clinical timeline.
We look forward to connecting with more innovators and partners over the next few days. Together, we can translate breakthrough science into transformative therapies and bring new hope to diabetes patients worldwide! ✨
Are you at BIO 2026? Let's connect! Drop us a message or schedule a meeting via the partnering system. 📩
#BIO2026 #Pharmasaga #Biotech #FirstInClass #DiabetesCare #ClinicalTrials #DrugDevelopment #Partnering #Innovation
#Pharmasaga #BIO2026 #BIOConvention #PS1 #PDIA4 #FirstInClass #Diabetes #Type2Diabetes #Biotech #DrugDevelopment #Licensing